Neurocrine Biosciences (NBIX) is stepping into a dense September investor circuit, with back to back presentations scheduled at healthcare conferences hosted by Wells Fargo, Cantor Fitzgerald, and Morgan Stanley in Boston and New York.
The recent US$157.22 share price sits on top of an 11.82% year to date share price return, with total shareholder return of 11.95% over one year and 65.03% over five years, pointing to momentum that has built steadily over the longer term rather than in short bursts around these conference appearances.
Scan a curated set of healthcare and biotech peers that, like Neurocrine Biosciences heading into this conference circuit, already have momentum on their side via the 35 high quality undervalued stocks.
Neurocrine Biosciences now trades at US$157.22 while analyst targets cluster closer to US$210, and internal fair value work implies an even wider gap. Is the recent strength already generous or still conservative?
Most Popular Narrative: 26% Undervalued
At a last close of $157.22 against a narrative fair value of about $213, the current Neurocrine Biosciences share price sits well below the valuation implied by the most widely followed storyline on the stock, which leans heavily on execution across its neurology portfolio.
A broad, late-stage and diversified CNS pipeline, including multiple Phase III programs targeting major depressive disorder and schizophrenia, leverages advances in precision medicine and increases visibility for future earnings, supporting potential future valuation multiple expansion.
See why 47 investors see Neurocrine Biosciences as 26% undervalued.
The fair value estimate of roughly $213 is built using a discount rate of 7.28%, which is used to bring projected cash flows and earnings back to today’s terms. That framework reflects analyst expectations for around 15.6% annual revenue growth, profit margins stepping up from 20.9% to 27.2%, and earnings potentially reaching about $1.4b by 2029, set against a future P/E multiple of roughly 20.3x.
Analysts tying this narrative together are effectively arguing that Neurocrine Biosciences could warrant a richer earnings multiple than the broader US biotech peer group at 17.3x, in part because of its mix of commercial franchises like INGREZZA and CRENESSITY alongside a late stage CNS pipeline. At the same time, their own work already bakes in risks around pricing pressure, payer scrutiny, portfolio concentration, and higher SG&A, so readers need to decide whether the embedded assumptions on growth, margins, and valuation multiples feel realistic given that backdrop.
Result: Fair Value of $213 (UNDERVALUED)
Still, that narrative cracks quickly if pricing pressure on INGREZZA and CRENESSITY bites harder than modeled or if late stage CNS trials miss key clinical endpoints.
Find out about the key risks to this Neurocrine Biosciences narrative.
Next Steps
If this Neurocrine Biosciences story feels compelling but incomplete, move quickly to pressure test the numbers yourself and stress the core assumptions. To see what optimism in the data looks like in practice, walk through the 4 key rewards.
Ready for more investment ideas beyond Neurocrine Biosciences?
If you stop at Neurocrine Biosciences, you risk missing other opportunities that fit your style, your risk appetite, and your income goals.
- Target potential mispricing by scanning companies that combine quality fundamentals with attractive valuations through the 35 high quality undervalued stocks.
- Strengthen portfolio resilience by focusing on businesses with robust finances using the list of solid balance sheet and fundamentals (23 results).
- Hunt for overlooked opportunities by filtering for financially sound under-the-radar prospects through the 15 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com